Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema - Full Text View

Sponsor:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00464685

Purpose

This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.

Condition	Intervention	Phase
Diabetic Macular Edema	Drug: Dexamethasone Drug: Sham injection	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Edema

Drug Information available for: Dexamethasone Dexamethasone acetate Doxiproct plus Dexamethasone Sodium Phosphate

U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:

Visual Acuity [ Time Frame: Month 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Macular Thickness (OCT) [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
Vessel leakage (FA) [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
Quality of Life [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
Time to retreatment [ Time Frame: Month 12 ] [ Designated as safety issue: No ]

Enrollment:	254
Study Start Date:	May 2007
Estimated Study Completion Date:	May 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Dexamethasone Intravitreal injection of Dexamethasone; 700 µg every 6 months; up to 2 doses
2: Sham Comparator	Drug: Sham injection Sham injection every 6 months; up to 2 doses

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age or older with diabetic macular edema
Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse)
Visual acuity in other eye no worse than 20/200

Exclusion Criteria:

Known anticipated need for ocular surgery within next 12 months
History of glaucoma or current high eye pressure requiring more than 1 medication
Uncontrolled systemic disease
Known steroid-responder
Use of systemic steroids - Use of Warfarin/Heparin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00464685

Locations

United States, California

Artesia, California, United States
Canada, British Columbia

Victoria, British Columbia, Canada

Sponsors and Collaborators

Allergan

Investigators

Study Director:

Medical Director

Allergan

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Allergan, Inc. ( Therapeutic Area Head )
Study ID Numbers:	206207-012
Study First Received:	April 20, 2007
Last Updated:	July 10, 2009
ClinicalTrials.gov Identifier:	NCT00464685 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Dexamethasone
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Eye Diseases
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Gastrointestinal Agents
Edema
Macular Degeneration
Retinal Degeneration
Antiemetics

Hormones
Glucocorticoids
Pharmacologic Actions
Macular Edema
Signs and Symptoms
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Central Nervous System Agents
Retinal Diseases
Dexamethasone acetate

ClinicalTrials.gov processed this record on November 05, 2009